Correspondence 0001213900-24-102320 from NewcelX Ltd. (NCEL)
NewcelX Ltd.
Date: Nov. 25, 2024 · CIK: 0001783036 · Accession: 0001213900-24-102320
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282788
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission Washington, D.C. 20549 Re: NLS Pharmaceutics Ltd. (CIK: 0001783036) Registration Statement on Form F-3 (File No. 333-282788) (the “Registration Statement”) Request for Acceleration of Effective Date
Dear Sir or Madam:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), NLS Pharmaceutics Ltd. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective on November 26, 2024 at 4:30 p.m., Eastern Time, or as soon as practicable thereafter.
The Registrant understands that the Securities and Exchange Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Ron Ben-Bassat, Esq. of Sullivan & Worcester LLP at (212) 660-5003 and that such effectiveness also be confirmed in writing.
Very truly yours,
NLS PHARMACEUTICS LTD.
Show Raw Text
CORRESP
1
filename1.htm
NLS Pharmaceutics Ltd.
The Circle 6
8058 Zurich, Switzerland
November 25, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: NLS Pharmaceutics Ltd. (CIK: 0001783036)
Registration Statement on Form F-3 (File No. 333-282788)
(the “Registration Statement”)
Request for Acceleration of Effective Date
Dear Sir or Madam:
Pursuant to Rule 461
under the Securities Act of 1933, as amended (the “Securities Act”), NLS Pharmaceutics Ltd. (the “Registrant”)
hereby requests that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective
on November 26, 2024 at 4:30 p.m., Eastern Time, or as soon as practicable thereafter.
The Registrant understands
that the Securities and Exchange Commission will consider this request for acceleration of the effective date of the Registration Statement
as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed
public offering of the securities specified in the Registration Statement.
The Registrant respectfully
requests that it be notified of such effectiveness by a telephone call to Ron Ben-Bassat, Esq. of Sullivan & Worcester LLP at (212)
660-5003 and that such effectiveness also be confirmed in writing.
Very truly yours,
NLS PHARMACEUTICS LTD.
By:
/s/ Nicole Fernandez–McGovern
Nicole Fernandez–McGovern, Chief Financial Officer